Immuron CEO Steven Lydeamore to Speak at TechKnow Invest Roadshow in Melbourne on July 27, 2026

Immuron's Proprietary Polyclonal Antibody Platform Technology

Immuron's core technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. The company produces highly specific immunoglobulins targeting enteric pathogens, with the key advantage of oral activity. This delivery method is critical in immunotherapy, as bovine immunoglobulin G (IgG) resists stomach acidity and digestive enzymes, enabling the therapeutic agents to act directly on bacteria in the gastrointestinal tract.

This platform technology supports the development of treatments across a wide range of infectious diseases by blocking viruses or bacteria at mucosal surfaces like the gastrointestinal tract and neutralising their toxins. This versatility has allowed Immuron to develop multiple product candidates targeting diverse disease indications, positioning it across several therapeutic markets within infectious disease and gastrointestinal health sectors.

TravelanAE: Immuron's Lead Commercial Product

TravelanAE, Immuron's flagship commercial product developed using its platform technology, is an orally administered passive immunotherapy designed to reduce the risk of travellers' diarrhoea. This digestive disorder is commonly caused by pathogenic bacteria and their toxins. TravelanAE is a purified tabletised preparation of hyper-immune bovine antibodies that, when taken with meals, binds to diarrhoea-causing bacteria, preventing colonisation and associated symptoms.

TravelanAE holds regulatory approvals in multiple major markets. In Australia, it is listed on the Australian Register for Therapeutic Goods (AUST L 106709) with indications to reduce travellers' diarrhoea risk, minor gastrointestinal disorders, and antimicrobial effects. In Canada, it is a licensed natural health product (NPN 80046016) indicated for travellers' diarrhoea risk reduction. In the United States, it is marketed as a dietary supplement for digestive tract protection. This multi-market regulatory status offers Immuron diverse international revenue streams.

IMM-124E Targeting Enterotoxigenic Escherichia coli (ETEC)

IMM-124E, the active ingredient in TravelanAE tablets, targets enterotoxigenic Escherichia coli (ETEC), a primary cause of travellers' diarrhoea. It is produced from colostrum of cattle immunised during pregnancy with a vaccine containing outer antigens from 13 human-derived ETEC strains. This generates high antibody levels against key surface antigens of common ETEC strains.

The hyperimmune colostrum IMM-124E contains polyclonal antibodies specific for ETEC antigens including lipopolysaccharide (LPS), colonisation factor antigen I (CFA-I), and flagellin. These antibodies demonstrate stronger binding and neutralising activity than those from unvaccinated cattle against a broad range of LPS antigens from the 13 ETEC serotypes. This targeted approach provides scientific support for TravelanAE's efficacy against the main bacteria causing travellers' diarrhoea.

Travellers' Diarrhoea: A Major Global Health Concern

Travellers' diarrhoea remains a significant global health issue, particularly among specific populations. Defined as three or more unformed stools in 24 hours plus symptoms like nausea, vomiting, cramps, fever, blood or mucus in stools, or fecal urgency occurring abroad or within ten days of return from resource-limited areas, it is the most common health problem for travellers to low- and middle-income regions.

US military personnel deployed overseas are particularly vulnerable, effectively constituting a long-term traveller population at risk of infectious disease outbreaks. Diarrhoea is the leading infectious disease threat to their health and readiness, with diarrhoeagenic E. coli, Campylobacter, and Shigella species being common causes. This disease burden in both civilian and military populations presents a substantial market opportunity for travellers' diarrhoea prevention products like TravelanAE.

IMM-529: Development for Recurrent Clostridioides difficile Infection (CDI)

Beyond TravelanAE, Immuron is advancing IMM-529 as an adjunct therapy combined with standard antibiotics to prevent and treat recurrent Clostridioides difficile infection (CDI). IMM-529 antibodies target C. difficile, potentially aiding infection clearance and faster restoration of normal gut flora, offering an attractive oral preventative for recurrent CDI, a major clinical challenge in healthcare settings.

In collaboration with Dr. Dena Lyras and Monash University, Immuron developed vaccines to produce bovine colostrum-derived antibodies targeting three key C. difficile virulence factors. Cows were immunised to generate hyperimmune colostrum with antibodies against toxin B, spores, and surface layer proteins of vegetative cells. This three-target strategy showed promising preclinical results including 80% prevention of primary disease (P=0.0052), 67% protection against recurrence (P < 0.01), and 78.6% treatment efficacy (P < 0.0001). IMM-529 antibodies cross-react with multiple human C. difficile strains, including hypervirulent types, indicating broad applicability.

IMM-529’s Therapeutic Potential Across CDI Disease Phases

IMM-529 is notable for demonstrating therapeutic potential in all three CDI phases: primary infection prevention, primary infection treatment, and recurrence prevention. This comprehensive approach targets critical disease progression points, offering competitive advantages in the CDI treatment market. Collaboration with Monash University enhances Immuron's scientific credibility in this indication.

The multi-target antibody approach exemplifies how Immuron’s platform can be tailored to address specific pathogenic mechanisms. By targeting multiple virulence factors simultaneously, this strategy may reduce bacterial resistance risk and improve clinical outcomes compared to single-target therapies under development elsewhere.

ProIBSAE Distribution Agreement Expands Gastrointestinal Health Portfolio

Immuron has broadened its gastrointestinal health offerings through an exclusive distribution agreement with Calmino Group AB for Australia and New Zealand for ProIBSAE. ProIBSAE is a certified medical device treating irritable bowel syndrome (IBS) symptoms such as abdominal pain, bloating, and irregular bowel movements including diarrhoea and constipation. It contains AVH200AE, derived from Aloe barbadensis, which supports the intestinal mucosal barrier via gel-forming components.

Calmino Group AB's usability study with 1,003 users found 94% reported ProIBSAE as helpful, 91% experienced daily life improvements, and 98% would recommend it. These satisfaction rates indicate strong market potential. With IBS affecting about 30% of the population, especially females, ProIBSAE distribution offers access to a large patient base in Australia and New Zealand.

Significant Market Opportunity in Digestive and Gastrointestinal Remedies

The gastrointestinal health market presents a substantial commercial opportunity for Immuron. The IBS treatment segment in Australia is part of the broader "Digestives & Intestinal Remedies" market, which generated approximately AU$221.14 million in revenue in 2025. This sizable market underscores potential for ProIBSAE and other gastrointestinal products in Immuron's portfolio.

Immuron’s diverse pipeline—including TravelanAE for travellers' diarrhoea prevention, IMM-529 for recurrent CDI treatment, and ProIBSAE for IBS symptom management—positions the company across multiple gastrointestinal and infectious disease market segments. This diversification reduces dependency on any single product and offers multiple growth avenues as products advance through development, regulatory approval, and commercialisation.

Investor Engagement and Leadership Dialogue at TechKnow Roadshow

The TechKnow Invest Roadshow presentation offers investors a structured forum to interact directly with CEO Steven Lydeamore and learn about Immuron’s strategic priorities, product development timelines, and market opportunities. Such roadshows enable public companies to communicate investment theses, update on pipeline progress, answer investor queries, and share management’s vision. Immuron’s participation demonstrates active investor relations and commitment to transparent shareholder communication.

Held at the Sofitel Melbourne on Collins in Victoria’s central business district, the venue provides easy access for institutional and retail investors throughout Melbourne and regional areas. Scheduled for 27 July 2026, the presentation will update investors on recent company developments and outlook. Interested investors can access the TechKnow Invest Roadshow programme through the organisers’ published resources.